Alzheimer's disease (AD) is a complex and heterogenous brain disease that affects multiple inter-related 53 biological processes. This complexity contributes, in part, to existing difficulties in the identification of 54 successful disease-modifying therapeutic strategies. To address this, systems approaches are being used to 55 characterize AD-related disruption in molecular state. To evaluate the consistency across these molecular 56 models, a consensus atlas of the human brain transcriptome was developed through coexpression meta-57 analysis across the AMP-AD consortium. Consensus analysis was performed across five coexpression 58 methods used to analyze RNA-seq data collected from 2114 samples across 7 brain regions and 3 research 59 studies. From this analysis, five consensus clusters were identified that described the major sources of 60 AD-related alterations in transcriptional state that were consistent across studies, methods, and samples.
INTRODUCTION

74
Alzheimer's Disease (AD) is a debilitating neurodegenerative disease affecting more than 5 million 75 Americans for which we lack effective long-term disease-modifying therapeutic strategies (Cummings et 
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This project aims to develop an atlas of AD-associated changes in molecular state that provides a 99 mechanism to evaluate the consistency and robustness of systems analyses and the use of their findings to 100 support AD target discovery. To this aim, we build on the resources and expertise gathered across the These modules are often comprised of genes involved in biological processes that interact and/or exhibit 111 coordinated activity in response to molecular and cellular states, pathological processes, and other factors 112 (Gaiteri et al., 2015) . Although distinct and important biology may be uniquely represented in any one of 113 these studies, meta-analysis provides a generalized illustration of the changes in transcriptional state 114 associated with AD in a manner that is robust to technical confound and study heterogeneity. An atlas 115 derived of cross-study AD-associated transcriptional modules can support target discovery by (1) 116 promoting target discovery across multiple distinct biological processes, (2) informing experimental 
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AMP-AD collection of human RNA-seq data. We analyzed existing transcriptional data generated from 123 post-mortem brain tissue homogenate from three separate sample sets including the Religious Order (PHG) in MSBB. Several differences in data collection and processing protocols across studies were 130 identified and accounted for during data processing and analysis (see Table 1 and Methods).
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Development of AD-related transcriptional modules by consensus coexpression network analysis. To 133 identify AD-related human transcriptional modules that were robustly observed in a generalized manner 134 across methods and studies, we performed a consensus analysis for all seven tissue types using five 135 coexpression analysis methodologies. These five distinct coexpression learning algorithms included: 
139
DLPFC: 450, FP: 393, IFG: 429, PHG: 370, STG: 336, TCX: 502, 10.7303/syn10309369.1). As 140 expected, similar coexpression structure was observed in each data set across methods, as indicated by 141 significant overlap in module memberships (Figure S1). Within each tissue, we next identified AD-142 related modules that were well-represented across analysis methodologies. This analysis was limited to 143 those modules that were significantly enriched for differentially expressed genes related to AD based on a 144 meta-analysis of differential expression across the seven brain regions (Methods). To do this, graph 145 clustering (Pons and Latapy, 2005) was performed on all modules within a tissue with an edge 146 betweenness community identification algorithm (Pons and Latapy, 2005) and weights from the Fisher's 147 exact test estimate (Methods, Figure S1 ). This meta-analysis of coexpression modules and differential 148 expression signatures identified 30 AD associated modules across the seven tissue types (CBE: 4, 149 DLPFC: 4, FP: 4, IFG: 4, PHG: 5, STG: 4, TCX: 5, 10.7303/syn11932957.1).
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To establish confidence that these consensus modules provided an improved and coherent 151 representation of AD-altered biology, they were evaluated for enrichment of gene sets previously 152 identified as relevant to AD (Figure 1 represented in these consensus clusters were not cell type specific, we did observe that genes represented 166 in cell-type specific gene signatures were grouped by cluster. As shown in Figure 2B 
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Heterogeneity in expression of consensus clusters between females and males. To evaluate whether 180 consensus clusters may prove useful in the identification of molecular heterogeneity in disease across 7 populations, we evaluated sex-specific differences across clusters in AD-related gene expression. Indeed, 182 sex-specific differential expression gene (DEG) sets -from a sex specific meta-analysis of differential 183 expression across the seven tissue types -were differentially enriched across the consensus clusters for 184 females vs. males (Figure 2D) . Consensus Clusters A and B demonstrated similar direction of DEGs 185 across sex through enrichment was stronger in females vs. males. This suggests that transcriptional 186 changes related to neuroinflammatory processes were common across the sexes, albeit more pronounced 187 in females. In contrast, the Consensus Clusters C and D were strongly enriched for genes altered in 188 females but not in males, suggesting that the overall association of these clusters with AD-related 189 differential expression was predominantly driven by females. Consensus Cluster E was enriched for genes 190 that were down-regulated in both male and female AD cases. This last cluster was moderately enriched 191 for genes that were up-regulated in male AD cases, with no such enrichment observed in females. These 
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In contrast, the modules identified by the other AMP-AD teams were all enriched within a single 220 consensus cluster. The Mayo and Mt Sinai teams each identified a separate module that was enriched for 221 oligodendrocyte signatures and that significantly overlapped with consensus cluster D ( Figure 2C , Table   222 S4). Notably, AD-related decreases in expression of genes within these two modules were reported by 223 each team. Because we observed sex-specific differences in AD gene expression in consensus cluster D 224 but results from sex-specific analyses were not reported by either team, we evaluated the Mayo and Mt.
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Sinai modules for sex-specificity. Indeed, the sex-specific pattern of AD-related expression were also 226 consistently observed in both the Mayo and Mt. Sinai modules. For the Mayo module, the effect size for 227 AD-related increased expression in females was much smaller than the effect size for AD-related 228 decreased expression in males (Table S8, 
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Finally, we evaluated enrichment for the one hundred genes nominated by the AMP-AD consortia 237 as the first set of candidates for AD target evaluation (https://agora.ampadportal.org). Because these 238 targets were selected in part based on analysis of these data, we expected to observe significant 239 enrichments within the consensus clusters. Interestingly, significant enrichment was observed (adjusted 240 P-value < 0.05), but this was specific to Consensus Clusters A, B, and C -those that were also enriched 241 for previously known AD biology processes. This suggests that the initial round of AMP-AD target 
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Identification of conserved human AD-related consensus clusters provides several benefits in the 298 pursuit of AD target discovery. First, they highlight the distinct aspects of brain biology that are 299 dysregulated with AD-including several that are not currently under active investigation for drug 300 development. While not all dysregulated pathways are likely to be causative, these results suggest that a 301 broader range of therapeutic hypotheses exist and serves to guide researchers to areas of biology that may 302 merit further pursuit. In this manner, the consensus clusters were used to demonstrate three major areas of 303 AD-related biology that are under active pursuit for drug discovery and a fourth area of interest. This 304 fourth, represented by Consensus Cluster D, had a complex subcluster architecture that may contain 305 several biological processes of interest for further pursuit. Indeed, two of these subclusters were 306 independently identified and are under active pursuit by the AMP-AD Mayo and Mt. Sinai target 307 discovery teams respectively. We note that the use consensus methodologies is explicitly designed to 308 identify signatures of disease that are most robust to technical and study specific heterogeneity and, as 309 such, can provide evidence to support costly drug discovery programs. This does not preclude the 310 12 relevance of other interesting biology that was not recapitulated across studies due to small effect size or 311 uneven representation across studies based on differences in sample ascertainment.
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In addition to evaluating diversity in AD therapeutic hypotheses, these human AD-related clusters 313 can be used to identify appropriate experimental model systems for further evaluation. Traditionally, AD 314 model systems have been developed through genetic perturbations of one or more AD-related pathways 315 (King, 2018) . While none of these models provides a complete recapitulation of human disease, many 316 provide a useful framework to evaluate dysregulation within specific pathways. Since a subset of human 317 co-expression clusters display conserved co-expression and/or overlapping differential expression in 318 brains from AD mouse models, these human clusters may help to assess the appropriateness of AD memberships. This module graph shows individual modules that are significantly enriched for at 752 least one DEG meta-analysis signature in DLPFC (ROSMAP). Each node is a module, and an 753 edge is drawn between modules if there is a statistically significant overlap of genes between the 754 two modules. The edge betweenness clustering algorithm identifies four robust meta modules, 755 which are colored green, purple, red and blue respectively. 756 757 Table S1 -Counts of number of individual coexpression modules identified by method and brain 758 region (10.7303/syn10309369.1). 759 760 Table S5 -Gene set enrichment results for aggregate modules and AD gene sets against genes 769 up-regulated in AD from the differential expressed gene sets from the random effect meta-770 analysis of differential expression. 771 33 772 Table S6 -Gene set enrichment results for aggregate modules and AD gene sets against genes 773 down-regulated in AD from the differential expressed gene sets from the random effect meta-774 analysis of differential expression. 775 776 Table S7 -Gene set enrichment results for aggregate modules and AD gene sets against genes 777 up-regulated in male AD from the differential expressed gene sets from the random effect meta-778 analysis of differential expression. 779 780 Table S8 -Gene set enrichment results for aggregate modules and AD gene sets against genes 781 up-regulated in female AD from the differential expressed gene sets from the random effect 782 meta-analysis of differential expression. 783 784 Table S9 -Gene set enrichment results for aggregate modules and AD gene sets against genes 785 down-regulated in female AD from the differential expressed gene sets from the random effect 786 meta-analysis of differential expression. 787 788 Table S10 -Gene set enrichment results for aggregate modules and AD gene sets against genes 789 down-regulated in male AD from the differential expressed gene sets from the random effect 790 meta-analysis of differential expression. 791
